About Salix Pharmaceuticals (NASDAQ:SLXP)
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.
Industry, Sector and Symbol
Industry Specialty & Advanced Pharmaceuticals
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-305.24%
Return on Assets-25.83%
Salix Pharmaceuticals (NASDAQ:SLXP) Frequently Asked Questions
What is Salix Pharmaceuticals' stock symbol?
Salix Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLXP."
How were Salix Pharmaceuticals' earnings last quarter?
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) posted its earnings results on Monday, March, 2nd. The specialty pharmaceutical company reported ($2.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $2.32. The specialty pharmaceutical company had revenue of $13 million for the quarter, compared to analysts' expectations of $187.97 million. Salix Pharmaceuticals had a negative return on equity of 305.24% and a negative net margin of 2,134.34%. During the same quarter in the prior year, the company earned $1.06 EPS. View Salix Pharmaceuticals' Earnings History.
Who are some of Salix Pharmaceuticals' key competitors?
Some companies that are related to Salix Pharmaceuticals include ConvaTec Group (CTEC), Advanced Accelerator Application (AAAP), Indivior (INDV), Mallinckrodt (MNK), Supernus Pharmaceuticals (SUPN), Aimmune Therapeutics (AIMT), Repligen (RGEN), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), Novan (NOVN), CorMedix (CRMD), Macrocure (MCUR), DARA Biosciences (DARA), Check Cap (CHEK) and Omthera Pharmaceuticals (OMTH).
How do I buy Salix Pharmaceuticals stock?
Shares of Salix Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Salix Pharmaceuticals' stock price today?
One share of Salix Pharmaceuticals stock can currently be purchased for approximately $172.81.
How big of a company is Salix Pharmaceuticals?
Salix Pharmaceuticals has a market capitalization of $10.94 billion.
How can I contact Salix Pharmaceuticals?
Salix Pharmaceuticals' mailing address is 8510 Colonnade Center Dr, RALEIGH, NC 27615-3050, United States. The specialty pharmaceutical company can be reached via phone at +1-919-8621000.
MarketBeat Community Rating for Salix Pharmaceuticals (SLXP)MarketBeat's community ratings are surveys of what our community members think about Salix Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Salix Pharmaceuticals (NASDAQ:SLXP) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Salix Pharmaceuticals (NASDAQ:SLXP) Earnings History and Estimates Chart
Salix Pharmaceuticals (NASDAQ SLXP) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/2/2015||Q414||($0.29)||($2.61)||$187.97 million||$13.00 million||View||N/A|
|11/6/2014||Q314||$1.56||$1.53||$394.00 million||$354.70 million||View||N/A|
|8/7/2014||Q214||$1.69||$1.59||$397.06 million||$382.00 million||View||Listen|
|5/8/2014||Q114||$0.91||$1.05||$372.91 million||$384.00 million||View||Listen|
|2/27/2014||Q413||$0.93||$1.06||$247.29 million||$257.60 million||View||Listen|
|11/7/2013||Q313||$0.86||$0.89||$239.70 million||$238.20 million||View||N/A|
|8/8/2013||Q2 2013||$0.81||$0.87||$226.34 million||$235.40 million||View||Listen|
|5/9/2013||Q1 2013||$0.67||$0.63||$205.94 million||$202.60 million||View||Listen|
|2/28/2013||Q4 2012||$0.78||$0.81||$199.41 million||$198.17 million||View||N/A|
|11/7/2012||Q312||$0.69||$0.95||$187.23 million||$185.13 million||View||N/A|
Salix Pharmaceuticals (NASDAQ:SLXP) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Salix Pharmaceuticals (NASDAQ:SLXP)
No dividend announcements for this company have been tracked by MarketBeat.com
Salix Pharmaceuticals (NASDAQ SLXP) Insider Trading and Institutional Ownership History
Salix Pharmaceuticals (NASDAQ SLXP) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/6/2015||Timothy J Creech||Insider||Sell||4,600||$157.67||$725,282.00|| |
|3/6/2015||William P Forbes||EVP||Sell||20,000||$157.96||$3,159,200.00|| |
|11/12/2014||William P Forbes||EVP||Sell||11,079||$95.05||$1,053,058.95|| |
|6/26/2014||Carolyn J Logan||CEO||Sell||53,057||$123.38||$6,546,172.66|| |
|4/22/2014||Alonzo Thomas D||Director||Sell||11,530||$110.89||$1,278,561.70|| |
|1/10/2014||Alonzo Thomas D||Director||Sell||12,050||$91.83||$1,106,551.50|| |
|1/9/2014||Adam Derbyshire||CFO||Sell||30,001||$91.48||$2,744,491.48|| |
|1/8/2014||William Forbes||EVP||Sell||8,000||$90.06||$720,480.00|| |
|1/7/2014||Rick Scruggs||EVP||Sell||8,463||$88.31||$747,367.53|| |
|1/7/2014||William Keane||Director||Sell||22,500||$88.31||$1,986,975.00|| |
|7/24/2013||William P Forbes||EVP||Sell||12,000||$70.93||$851,160.00|| |
|4/10/2013||William P Forbes||EVP||Sell||8,673||$49.37||$428,186.01|| |
|12/26/2012||Adam C Derbyshire||CFO||Sell||60,000||$41.44||$2,486,400.00|| |
|11/13/2012||Mark A Sirgo||Director||Sell||3,450||$40.53||$139,828.50|| |
Salix Pharmaceuticals (NASDAQ SLXP) News Headlines
Salix Pharmaceuticals (NASDAQ:SLXP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Salix Pharmaceuticals (NASDAQ:SLXP) Income Statement, Balance Sheet and Cash Flow Statement
Salix Pharmaceuticals (NASDAQ SLXP) Stock Chart for Saturday, December, 16, 2017